dr mark hyman glp 1 Dr. on GLP‑1 drugs facing multiple lawsuits Dr. Mark Hyman joins Levels

Clinical Points GLP-1 receptor agonists (GLP-1 RAs), such as exenatide, demonstrated efficacy in reducing heavy drinking days and total alcohol intake in individuals with obesity-related alcohol use disorders, suggesting a potential role for GLP-1 RAs in targeted treatments for alcohol dependency, particularly in patients with specific metabolic profiles

By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline

Final thoughts If youre reading this because youre considering GLP-1 therapy, or already using it and want a more comprehensive approach, here are key take-aways: GLP-1s can be powerful tools for glycemic control and weight/metabolic healthbut they carry side-effects and nutrient risks

Patti, M

And what happens when the algorithms that drive social media engagement also start driving demand for pharmaceuticals

Approximately 0.5 MBq/kg [ 68 Ga]Ga-DO3A-Exendin-4 (0.47 0.03 MBq/kg), corresponding to 0.13 0.04 g/kg peptide, was administered intravenously as a bolus